Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011860 (
type 2 diabetes
)
57,723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Microvascular diseases, such as retinopathies, neuropathies, and nephropathies, are a devastating consequence of type 1 and
type 2 diabetes
. The etiology of diabetes-associated microvascular dysfunction is poorly understood, and, likewise, treatment modalities for these disorders are limited. Interestingly, proinsulin C-peptide has been shown to play a protective role against diabetes-associated complications in experimental animals and in diabetic humans and is thus an attractive therapeutic target. However, an important step in the development of C-peptide-based therapeutics is identification of the C-peptide receptor, which is likely a G protein-coupled receptor (GPCR). Using a unique Deductive Ligand-Receptor Matching Strategy, we sought to determine whether one of the known orphan GPCRs is essential for C-peptide signaling. Knockdown of
GPR146
, but not GPR107 or GPR160, blocked C-peptide-induced cFos expression in KATOIII cells. Furthermore, stimulation with C-peptide caused internalization of
GPR146
, and examples of punctate colocalization were observed between C-peptide and
GPR146
on KATOIII cell membranes. These data indicate that
GPR146
is likely a part of the C-peptide signaling complex and provide a platform for the elucidation of the C-peptide signalosome.
...
PMID:Evidence for an interaction between proinsulin C-peptide and GPR146. 2375 46
Microvascular diseases, such as retinopathies, neuropathies, and nephropathies, are a devastating consequence of type 1 and
type 2 diabetes
. The etiology of diabetes-associated microvascular dysfunction is poorly understood, and, likewise, treatment modalities for these disorders are limited. Interestingly, proinsulin C-peptide has been shown to play a protective role against diabetes-associated complications in experimental animals and in diabetic humans and is thus an attractive therapeutic target. However, an important step in the development of C-peptide-based therapeutics is identification of the C-peptide receptor, which is likely a G protein-coupled receptor (GPCR). Using a unique Deductive Ligand-Receptor Matching Strategy, we sought to determine whether one of the known orphan GPCRs is essential for C-peptide signaling. Knockdown of
GPR146
, but not GPR107 or GPR160, blocked C-peptide-induced cFos expression in KATOIII cells. Furthermore, stimulation with C-peptide caused internalization of
GPR146
, and examples of punctate colocalization were observed between C-peptide and
GPR146
on KATOIII cell membranes. These data indicate that
GPR146
is likely a part of the C-peptide signaling complex and provide a platform for the elucidation of the C-peptide signalosome.
...
PMID:Evidence for an interaction between proinsulin C-peptide and GPR146. 2398 Feb 58
ATP release from erythrocytes in response to reduced oxygen (O2) tension stimulates local vasodilation, enabling these cells to direct perfusion to areas in skeletal muscle in need of O2. Erythrocytes of humans with
type 2 diabetes
do not release ATP in response to low O2. Both C-peptide and insulin individually inhibit low O2-induced ATP release from healthy human erythrocytes, yet when coadministered at physiological concentrations and ratios, no inhibition is seen. Here, we determined: that 1) erythrocytes of healthy humans and humans with
type 2 diabetes
possess a C-peptide receptor (
GPR146
), 2) the combination of C-peptide and insulin at physiological ratios rescues low O2-induced ATP release from erythrocytes of humans with
type 2 diabetes
, 3) residual C-peptide levels reported in humans with
type 2 diabetes
are not adequate to rescue low O2-induced ATP release in the presence of 1 nM insulin, and 4) the effects of C-peptide and insulin are neither altered by increased glucose levels nor explained by changes in erythrocyte deformability. These results suggest that the addition of C-peptide to the treatment regimen for
type 2 diabetes
could have beneficial effects on tissue oxygenation, which would help to ameliorate the concomitant peripheral vascular disease.
...
PMID:Low O2-induced ATP release from erythrocytes of humans with type 2 diabetes is restored by physiological ratios of C-peptide and insulin. 2508 Apr 97